![]() |
市场调查报告书
商品编码
1965469
非PVC输液袋市场-全球产业规模、份额、趋势、机会、预测:按产品类型、材料、含量、地区和竞争格局划分,2021-2031年Non-PVC IV Bags Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Material, By Content, By Region & Competition, 2021-2031F |
||||||
全球非PVC输液袋市场预计将从2025年的31亿美元成长到2031年的45.6亿美元,复合年增长率为6.64%。
这些无菌输液容器采用聚丙烯和聚乙烯等热可塑性橡胶製造,并经过特殊设计,不含聚氯乙烯(PVC) 和邻苯二甲酸二(2-乙基己基)酯 (DEHP)。市场成长主要受以下因素驱动:为消除医疗废弃物焚烧过程中有害戴奥辛排放製定的严格监管要求;以及临床上迫切需要能够防止在输注高敏感性抗癌药物和亲油性药物过程中化学物质渗漏的容器。根据 Practice Greenhealth 统计,截至 2024 年,在已报告的医疗机构中,包括输液袋在内的肠外输液产品线中不含 DEHP 和 PVC 的比例中位数已达到 38%。
| 市场概览 | |
|---|---|
| 预测期 | 2027-2031 |
| 市场规模:2025年 | 31亿美元 |
| 市场规模:2031年 | 45.6亿美元 |
| 复合年增长率:2026-2031年 | 6.64% |
| 成长最快的细分市场 | 多重腔 |
| 最大的市场 | 北美洲 |
然而,目前阻碍全球非PVC输液袋市场扩张的主要障碍是其与传统材料相比较高的製造成本。先进聚烯的复杂製造流程以及不断上涨的原物料价格导致其价格溢价,阻碍了注重预算的医疗机构采用。因此,儘管人们意识到传统PVC输液袋存在环境方面的弊端,但采购决策往往优先考虑即时的经济效益。
对化学物质渗漏的更严格监管以及对患者安全日益增长的担忧,正在从根本上改变全球非聚氯乙烯会释放致癌性的戴奥辛,所带来的环境风险进一步加速了这个趋势。这种材料替代的规模庞大。根据「无害医疗」(Health Care Without Harm)组织预测,到2024年7月,PVC医疗设备将占全球医疗设备的26%,这为用更安全的替代品取代它们提供了巨大的机会。随着监管机构实施更严格的标准,製造商正在重新设计其产品线,以确保更好的药物相容性,并将对脆弱患者的毒性风险降至最低。
同时,人们对永续医疗包装的日益关注正推动着可回收性更强的非PVC材料的普及。与PVC不同,聚丙烯等热可塑性橡胶能够实现更清洁的处置,并支持循环经济的实施。百特国际于2023年12月开展的试验计画充分体现了该产业对环境管理的承诺,该计画成功地将超过6吨的输液袋废弃物从掩埋转移出去。为了满足市场对这些环保产品日益增长的需求,主要市场参与者正在大幅扩大其产能。例如,2024年11月,ICU Medical宣布与大冢製药株式会社成立合资企业,利用其年产能约14亿件的综合生产网络,加强现代静脉输液治疗的全球供应链。
非聚氯乙烯(PVC)输液袋由于製造成本高于传统材料,在市场扩张方面面临重大障碍。这些无菌容器的生产需要先进的聚烯和专门的加工技术,因此其成本必然高于大规模生产的传统聚氯乙烯(PVC)产品。这种价格差异迫使医疗机构在环境目标和财务永续性之间做出艰难抉择,往往导致他们为了保障营运资金而继续使用成本较低的传统输液方案。
医疗保健产业的紧缩环境进一步加剧了这些经济压力。随着营运成本的上升,采购预算捉襟见肘。美国医院协会 (AHA) 报告称,到 2024 年,医院总支出将增加 5.1%,远超过整体通货膨胀率。面对日益沉重的财务负担,医疗机构管理者被迫仔细审查每项耗材,以维持获利能力。因此,非 PVC 材质的造口袋溢价更容易受到成本削减措施的影响,儘管临床上具有许多益处,但越来越多的医疗机构仍在推迟采用。这直接阻碍了非 PVC 造口袋市场的整体成长。
即用型(RTA)静脉输液的出现,从根本上改变了市场动态,显着降低了医院药房运作中的低效环节。与传统的配製方式不同,RTA製剂提供无菌预混处方,避免了污染风险和给药错误等问题,大幅缩短了医护人员的配药时间和人事费用。这种对便利性和安全性的追求,促使製造商拓展其非PVC预填充容器的产品线,以优化临床处理效率,同时符合灭菌标准。例如,2024年7月,Amneel Pharmaceuticals宣布其新型无防腐剂即用型磷酸钾注射液获得美国FDA核准。该产品旨在简化给药流程,最大限度地减少临床医生通常需要的配製步骤。
同时,生产线的节能已成为优先事项。製造商正致力于减少生产过程本身(而非包装袋材料)的碳足迹。业界领导企业正透过采用可再生能源技术维修设备并优化热处理工艺,减少范围 1 和范围 2 的排放,使其营运与全球净零排放目标保持一致。这一趋势的重点在于降低热可塑性橡胶所需的能耗,并透过卓越的製造技术来实现环境目标。贝朗在 2024 年企业报告中强调,自 2020 年以来,透过有针对性的营运改善和资源节约措施,集团已成功将二氧化碳当量排放排放减少了 9.6%。
The Global Non-PVC IV Bags Market is projected to expand from a valuation of USD 3.10 Billion in 2025 to USD 4.56 Billion by 2031, reflecting a CAGR of 6.64%. These sterile fluid containers are crafted from thermoplastic elastomers like polypropylene or polyethylene, specifically designed to exclude polyvinyl chloride and di-2-ethylhexyl phthalate (DEHP). This market growth is largely driven by strict regulatory mandates seeking to eliminate toxic dioxin emissions during medical waste incineration, alongside the urgent clinical need for containers that prevent chemical leaching when administering sensitive oncological or lipophilic drugs. According to Practice Greenhealth, in 2024, the median share of DEHP- and PVC-free product lines within the parenteral infusion category, which includes IV bags, stood at 38% among reporting healthcare facilities.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 3.10 Billion |
| Market Size 2031 | USD 4.56 Billion |
| CAGR 2026-2031 | 6.64% |
| Fastest Growing Segment | Multi Chamber |
| Largest Market | North America |
However, a major obstacle currently slowing the wider expansion of the Global Non-PVC IV Bags Market is the higher production cost compared to legacy materials. The sophisticated manufacturing processes and increased raw material prices associated with advanced polyolefins result in a price premium that deters adoption in budget-conscious healthcare systems. Consequently, procurement decisions frequently prioritize the immediate economic efficiency of traditional PVC options, despite the known environmental disadvantages associated with them.
Market Driver
Tightening regulatory restrictions and rising patient safety concerns regarding chemical leaching are fundamentally reshaping the Global Non-PVC IV Bags Market. Healthcare systems are actively phasing out polyvinyl chloride containers to reduce risks associated with di-2-ethylhexyl phthalate (DEHP), a plasticizer linked to endocrine disruption, a shift further accelerated by the environmental hazards of incinerating chlorinated plastics which release carcinogenic dioxins. The scale of this material substitution is substantial; Health Care Without Harm noted that in July 2024, PVC medical devices comprised 26% of devices globally, presenting a massive opportunity for replacement with safer alternatives. As regulators enforce stricter standards, manufacturers are reformulating product lines to ensure superior drug compatibility and minimize toxicity risks for vulnerable patients.
Simultaneously, the increasing focus on sustainable medical packaging is boosting the adoption of non-PVC materials that offer improved recyclability. Unlike PVC, thermoplastic elastomers such as polypropylene facilitate cleaner disposal and support circular economy applications. This industry commitment to environmental stewardship was highlighted by Baxter International Inc., which concluded a pilot program in December 2023 that successfully diverted over 6 tons of IV bag waste from landfills. To meet the escalating demand for these eco-friendly products, key market players are significantly expanding their manufacturing capacities; for instance, ICU Medical, Inc. announced a joint venture with Otsuka Pharmaceutical Factory in November 2024 to leverage a combined production network of roughly 1.4 billion annual units, strengthening the global supply chain for modern infusion therapies.
Market Challenge
The higher production expense of non-PVC IV bags relative to legacy materials constitutes a significant barrier to market expansion. Manufacturing these sterile containers requires advanced polyolefins and specialized fabrication technologies that are inherently more expensive than the mass production of traditional polyvinyl chloride. This price disparity forces healthcare providers to face a difficult trade-off between environmental objectives and financial viability, often resulting in the retention of cheaper, conventional IV solutions to maintain operational liquidity.
This economic pressure is exacerbated by the tightening financial landscape of the medical sector, where rising operational costs are squeezing procurement budgets. The American Hospital Association reported that in 2024, total hospital expenses grew by 5.1%, significantly outpacing the general inflation rate. Confronted with such escalating financial burdens, healthcare administrators are compelled to scrutinize every supply line item to preserve margins. Consequently, the premium attached to non-PVC bags renders them a target for cost-containment measures, causing facilities to defer adoption despite the clinical advantages, thereby directly hampering the broader growth of the non-PVC market.
Market Trends
The emergence of Ready-to-Administer (RTA) IV Solutions is fundamentally altering market dynamics by resolving critical inefficiencies in hospital pharmacy workflows. In contrast to traditional compounding, which carries risks of contamination and dosing errors, RTA formats offer sterile, pre-mixed formulations that significantly reduce preparation time and labor costs for healthcare providers. This shift toward convenience and safety is driving manufacturers to expand their portfolios of pre-filled non-PVC containers, ensuring compliance with sterility standards while optimizing clinical throughput. For example, Amneal Pharmaceuticals announced in July 2024 that it received U.S. FDA approval for a new preservative-free, ready-to-use Potassium Phosphates Injection IV bag, designed to streamline administration and minimize the compounding steps typically required by clinicians.
Parallel to this, the implementation of energy-efficient production lines has emerged as a priority, as manufacturers strive to lower the carbon footprint of the fabrication process itself, distinct from the bag materials. Industry leaders are retrofitting facilities with renewable energy technologies and optimizing thermal processes to decrease Scope 1 and 2 emissions, aligning operational performance with global net-zero targets. This trend focuses on reducing the energy intensity required to mold thermoplastic elastomers, addressing environmental goals through manufacturing excellence. B. Braun highlighted this in its 2024 corporate report, stating that its global group successfully reduced CO2 equivalent emissions by 9.6% since 2020 through targeted operational improvements and resource conservation measures.
Report Scope
In this report, the Global Non-PVC IV Bags Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Non-PVC IV Bags Market.
Global Non-PVC IV Bags Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: